Skip to main content


Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Cardamonin inhibits breast cancer growth by repressing HIF-1α-dependent metabolic reprogramming

Fig. 3

Cardamonin induces metabolic reprogramming in MDA-MB-231 cells before apoptosis occurring. a, b Cardamonin (20 μM) treatment decreased mitochondrial membrane potential (MMP) in MDA-MB-231 cells; the reduction of MMP was detected by JC-1 (10 μM) at 9 h after treatment. c CCK analysis showed that cardamonin (20 μM) inhibited cell viability in MDA-MB-231 cells at 9 h after treatment. d, e Treatment with cardamonin (20, 40 and 80 μM) for 6 h decreased glucose uptake in MDA-MB-231 cells in a dose-dependent manner. f Cardamonin (20 μM) treatment for 6 h decreased intracellular and extracellular lactate levels of MDA-MB-231 cells. g, h Treatment with cardamonin (20 μM) for 3 and 6 h significantly enhanced OCR in MDA-MB-231 cells. OCR and GlycoPER were detected by the Agilent’s Seahorse Bioscience XF96 Extracellular Flux Analyzer. i, j Cardamonin (20 μM) treatment for 12 h reduced glyco-PER of MDA-MB-231 cells. k, l Treatment with cardamonin (20 μM) for 6 h significantly reduced protein expression of HIF-1α and its metabolism related target genes. Data are shown as mean ± SD; *, P < 0.05, **, P < 0.01; ***, P < 0.001, compared with control. n ≥ 3. Scale bar, 50 μm

Back to article page